Gail Boxer Marcus Sells 4,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,000 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $164.44, for a total value of $657,760.00. Following the sale, the director now directly owns 5,704 shares of the company's stock, valued at $937,965.76. This trade represents a 41.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, May 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $151.61, for a total value of $606,440.00.
• On Tuesday, April 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $140.78, for a total value of $563,120.00.

Natera Price Performance

Shares of Natera stock traded up $0.99 during midday trading on Friday, hitting $165.34. 729,330 shares of the company were exchanged, compared to its average volume of 1,410,918. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market cap of $22.58 billion, a P/E ratio of -93.94 and a beta of 1.74. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The firm has a 50 day simple moving average of $154.56 and a 200-day simple moving average of $158.53.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera's revenue was up 36.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.56) EPS. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Strs Ohio bought a new position in Natera in the 1st quarter valued at $8,992,000. Geneos Wealth Management Inc. raised its position in Natera by 142.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company's stock valued at $155,000 after purchasing an additional 646 shares during the last quarter. IFM Investors Pty Ltd bought a new position in Natera in the 1st quarter valued at $3,498,000. Intech Investment Management LLC raised its position in Natera by 591.4% in the 1st quarter. Intech Investment Management LLC now owns 85,369 shares of the medical research company's stock valued at $12,072,000 after purchasing an additional 73,021 shares during the last quarter. Finally, Focus Partners Wealth raised its position in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. Morgan Stanley raised their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Barclays raised their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Robert W. Baird raised their target price on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, UBS Group raised their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.